These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7466815)

  • 1. Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide.
    Terishimna M; Takeichi N; Suzuki K; Itaya T; Gotohoda E; Kobayashi H
    Tohoku J Exp Med; 1980 Nov; 132(3):355-61. PubMed ID: 7466815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide (author's transl)].
    Terashima M
    Hokkaido Igaku Zasshi; 1980 Nov; 55(6):495-9. PubMed ID: 6456215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.
    Hosokawa M; Okayasu T; Ikeda K; Katoh H; Suzuki Y; Kobayashi H
    Cancer Res; 1983 May; 43(5):2301-5. PubMed ID: 6831454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs.
    Komatsumoto M; Hosokawa M; Okada F; Okayasu T; Tanabe T; Kobayashi H
    Cancer Immunol Immunother; 1991; 33(5):279-84. PubMed ID: 1714345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Augmentation of specific anti-tumor immunity by immunization with xenogenized tumor cells and its application to the experimental cancer treatment (author's transl)].
    Okayasu T
    Hokkaido Igaku Zasshi; 1981 Nov; 56(6):615-22. PubMed ID: 7338338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of cyclophosphamide on in vitro correlates of tumor immunity.
    Steele G; Sjögren HO; Ankerst J
    Int J Cancer; 1974 Dec; 14(6):743-52. PubMed ID: 4377004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enhancement of immune response by an antitumor agent, cyclophosphamide].
    Nitta K; Tanaka T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):706-13. PubMed ID: 2938546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The active immunotherapy of a 3-methylcholanthrene-induced rat tumor with Friend virus-infected (xenogenized) tumor cells.
    Okayasu T; Hosokawa M; Tanabe T; Kobayashi H
    Jpn J Cancer Res; 1986 Aug; 77(8):817-24. PubMed ID: 3093428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cyclophosphamide on tumor cell sensitivity to the action of immunological effectors.
    Culo F; Marić M; Morović-Vergles J
    In Vivo; 1995; 9(5):439-46. PubMed ID: 8900921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-mediated immunity to chemically xenogenized tumors--IV. Production of lymphokine activity by, and in response to, highly immunogenic cells.
    Romani L; Puccetti P; Grohmann U; Cenci E; Mage MG; Fioretti MC
    Int J Immunopharmacol; 1989; 11(5):537-42. PubMed ID: 2807629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance induction of alloreactivity by portal venous inoculation with allogeneic cells followed by the injection of cyclophosphamide. I. Specific suppression of alloreactive cytotoxic and delayed-type hypersensitivity responses as well as allograft rejection.
    Qian JH; Kokudo S; Sato S; Hamaoka T; Fujiwara H
    Transplantation; 1987 Apr; 43(4):538-43. PubMed ID: 3495052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
    Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
    J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12.
    Le HN; Lee NC; Tsung K; Norton JA
    J Immunol; 2001 Dec; 167(12):6765-72. PubMed ID: 11739491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan.
    Morikawa K; Hamada J; Itaya T; Ishikawa M; Takeichi N; Hosokawa M; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(1):18-22. PubMed ID: 3345537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
    Awwad M; North RJ
    Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of cyclophosphamide on the rejection of allogenic rat kidney transplants. An in vitro study of cell-bound and antibody-mediated immunity.
    Husberg BS
    Clin Exp Immunol; 1972 Apr; 10(4):697-711. PubMed ID: 4556105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination.
    Radojcic V; Bezak KB; Skarica M; Pletneva MA; Yoshimura K; Schulick RD; Luznik L
    Cancer Immunol Immunother; 2010 Jan; 59(1):137-48. PubMed ID: 19590872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.